Review of the Literature and Proposed Guidelines for the Use of Oral Ribavirin as Postexposure Prophylaxis for Lassa Fever
Identifieur interne : 002625 ( Main/Exploration ); précédent : 002624; suivant : 002626Review of the Literature and Proposed Guidelines for the Use of Oral Ribavirin as Postexposure Prophylaxis for Lassa Fever
Auteurs : Daniel G. Bausch [États-Unis] ; Christiane M. Hadi [États-Unis] ; Sheik Humarr Khan [Sierra Leone] ; Juan J. L. Lertora [États-Unis]Source :
- Clinical Infectious Diseases [ 1058-4838 ] ; 2010.
Abstract
Lassa fever is an acute viral hemorrhagic illness; the virus is endemic in West Africa and also of concern with regard to bioterrorism. Transmission of Lassa virus between humans may occur through direct contact with infected blood or bodily secretions. Oral administration of the antiviral drug ribavirin is often considered for postexposure prophylaxis, but no systematically collected data or uniform guidelines exist for this indication. Furthermore, the relatively low secondary attack rates for Lassa fever, the restriction of the area of endemicity to West Africa, and the infrequency of high-risk exposures make it unlikely that controlled prospective efficacy trials will ever be possible. Recommendations for postexposure use of ribavirin can therefore be made only on the basis of a thorough understanding and logical extrapolation of existing data. Here, we review the pertinent issues and propose guidelines based on extensive review of the literature, as well as our experience in this field. We recommend oral ribavirin postexposure prophylaxis for Lassa fever exclusively for definitive high-risk exposures. These guidelines may also serve for exposure to other hemorrhagic fever viruses susceptible to ribavirin.
Url:
DOI: 10.1086/657315
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001836
- to stream Istex, to step Curation: 001836
- to stream Istex, to step Checkpoint: 000878
- to stream Main, to step Merge: 002664
- to stream Main, to step Curation: 002625
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Review of the Literature and Proposed Guidelines for the Use of Oral Ribavirin as Postexposure Prophylaxis for Lassa Fever</title><author><name sortKey="Bausch, Daniel G" sort="Bausch, Daniel G" uniqKey="Bausch D" first="Daniel G." last="Bausch">Daniel G. Bausch</name></author><author><name sortKey="Hadi, Christiane M" sort="Hadi, Christiane M" uniqKey="Hadi C" first="Christiane M." last="Hadi">Christiane M. Hadi</name></author><author><name sortKey="Khan, Sheik Humarr" sort="Khan, Sheik Humarr" uniqKey="Khan S" first="Sheik Humarr" last="Khan">Sheik Humarr Khan</name></author><author><name sortKey="Lertora, Juan J L" sort="Lertora, Juan J L" uniqKey="Lertora J" first="Juan J. L." last="Lertora">Juan J. L. Lertora</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:C7D2CE02F499BAE7AC393EEB46844E3B83D04FDC</idno><date when="2010" year="2010">2010</date><idno type="doi">10.1086/657315</idno><idno type="url">https://api.istex.fr/ark:/67375/HXZ-P0G00WDW-F/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">001836</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001836</idno><idno type="wicri:Area/Istex/Curation">001836</idno><idno type="wicri:Area/Istex/Checkpoint">000878</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000878</idno><idno type="wicri:doubleKey">1058-4838:2010:Bausch D:review:of:the</idno><idno type="wicri:Area/Main/Merge">002664</idno><idno type="wicri:Area/Main/Curation">002625</idno><idno type="wicri:Area/Main/Exploration">002625</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Review of the Literature and Proposed Guidelines for the Use of Oral Ribavirin as Postexposure Prophylaxis for Lassa Fever</title><author><name sortKey="Bausch, Daniel G" sort="Bausch, Daniel G" uniqKey="Bausch D" first="Daniel G." last="Bausch">Daniel G. Bausch</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Louisiane</region></placeName><wicri:cityArea>Tulane University Health Sciences Center, New Orleans</wicri:cityArea></affiliation><affiliation wicri:level="1"><country wicri:rule="url">États-Unis</country></affiliation><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Louisiane</region></placeName><wicri:cityArea>Reprints or correspondence: Dr Daniel G. Bausch, Tulane School of Public Health and Tropical Medicine, Dept of Tropical Medicine, SL-17, 1430 Tulane Ave, New Orleans</wicri:cityArea></affiliation></author><author><name sortKey="Hadi, Christiane M" sort="Hadi, Christiane M" uniqKey="Hadi C" first="Christiane M." last="Hadi">Christiane M. Hadi</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Louisiane</region></placeName><wicri:cityArea>Tulane University Health Sciences Center, New Orleans</wicri:cityArea></affiliation></author><author><name sortKey="Khan, Sheik Humarr" sort="Khan, Sheik Humarr" uniqKey="Khan S" first="Sheik Humarr" last="Khan">Sheik Humarr Khan</name><affiliation wicri:level="1"><country xml:lang="fr">Sierra Leone</country><wicri:regionArea>Kenema Government Hospital, Ministry of Health and Sanitation, Kenema</wicri:regionArea><wicri:noRegion>Kenema</wicri:noRegion></affiliation></author><author><name sortKey="Lertora, Juan J L" sort="Lertora, Juan J L" uniqKey="Lertora J" first="Juan J. L." last="Lertora">Juan J. L. Lertora</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>National Institutes of Health (NIH) Clinical Center, NIH, Bethesda</wicri:cityArea></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Clinical Infectious Diseases</title><title level="j" type="abbrev">Clin Infect Dis.</title><idno type="ISSN">1058-4838</idno><idno type="eISSN">1537-6591</idno><imprint><publisher>The University of Chicago Press</publisher><date type="published">2010</date><biblScope unit="vol">51</biblScope><biblScope unit="issue">12</biblScope><biblScope unit="page" from="1435">1435</biblScope><biblScope unit="page" to="1441">1441</biblScope></imprint><idno type="ISSN">1058-4838</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1058-4838</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract">Lassa fever is an acute viral hemorrhagic illness; the virus is endemic in West Africa and also of concern with regard to bioterrorism. Transmission of Lassa virus between humans may occur through direct contact with infected blood or bodily secretions. Oral administration of the antiviral drug ribavirin is often considered for postexposure prophylaxis, but no systematically collected data or uniform guidelines exist for this indication. Furthermore, the relatively low secondary attack rates for Lassa fever, the restriction of the area of endemicity to West Africa, and the infrequency of high-risk exposures make it unlikely that controlled prospective efficacy trials will ever be possible. Recommendations for postexposure use of ribavirin can therefore be made only on the basis of a thorough understanding and logical extrapolation of existing data. Here, we review the pertinent issues and propose guidelines based on extensive review of the literature, as well as our experience in this field. We recommend oral ribavirin postexposure prophylaxis for Lassa fever exclusively for definitive high-risk exposures. These guidelines may also serve for exposure to other hemorrhagic fever viruses susceptible to ribavirin.</div></front></TEI><affiliations><list><country><li>Sierra Leone</li><li>États-Unis</li></country><region><li>Louisiane</li><li>Maryland</li></region></list><tree><country name="États-Unis"><region name="Louisiane"><name sortKey="Bausch, Daniel G" sort="Bausch, Daniel G" uniqKey="Bausch D" first="Daniel G." last="Bausch">Daniel G. Bausch</name></region><name sortKey="Bausch, Daniel G" sort="Bausch, Daniel G" uniqKey="Bausch D" first="Daniel G." last="Bausch">Daniel G. Bausch</name><name sortKey="Bausch, Daniel G" sort="Bausch, Daniel G" uniqKey="Bausch D" first="Daniel G." last="Bausch">Daniel G. Bausch</name><name sortKey="Hadi, Christiane M" sort="Hadi, Christiane M" uniqKey="Hadi C" first="Christiane M." last="Hadi">Christiane M. Hadi</name><name sortKey="Lertora, Juan J L" sort="Lertora, Juan J L" uniqKey="Lertora J" first="Juan J. L." last="Lertora">Juan J. L. Lertora</name></country><country name="Sierra Leone"><noRegion><name sortKey="Khan, Sheik Humarr" sort="Khan, Sheik Humarr" uniqKey="Khan S" first="Sheik Humarr" last="Khan">Sheik Humarr Khan</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002625 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002625 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:C7D2CE02F499BAE7AC393EEB46844E3B83D04FDC
|texte= Review of the Literature and Proposed Guidelines for the Use of Oral Ribavirin as Postexposure Prophylaxis for Lassa Fever
}}
| This area was generated with Dilib version V0.6.33. |  |